Second, some baseline characteristics, such as included population, duration of study, background therapies and quality of studies are different across included RCTs which are particularly relevant as cardiometabolic effects of GLP-1RAs may differ when these agents are added to insulin, metformin, sulfonylureas, DDP-4 inhibitors and SGLT-2 inhibitors
In clinical trials, patients receiving both medications achieved average weight reductions of 12-18% of body weight over 52 weeks, compared to 5-8% with metformin alone
A network meta-analysis of 22 RCTs of 2,258 participants found that lean mass accounted for roughly 25% of total weight lost on GLP-1 drugs, and DXA body-composition substudies report a range of 2640%
Coughing does not appear on the list of common side effects that affect the majority of users
GLP-1 medications are not substitutes for prescribed medical treatment
A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
